Award Winning Manufacturing Capabilities

For several years, Boston Scientific has been rigorously preparing to meet the demands that TAXUS production will place on our domestic and international manufacturing capabilities. During this period of transition – as we developed the capability for mass production of a complex device-drug product – our capital investment in facilities, equipment and infrastructure increased dramatically. In the past two years alone, we have devoted nearly $100 million – approximately one-third – of our capital budget to TAXUS-related improvements, with the following results: